BeOne Medicines Ltd. Class A
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- John V. Oyler
- Full Time Employees
- 12,000
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Aeschengraben 27 Basel BL Switzerland 4051
- IPO Date
- Feb 3, 2016
- Website
- beonemedicines.com
- Similar Companies
- Business
- BeOne Medicines Ltd. (688235.SS), formerly BeiGene Ltd., operates as a global oncology company that discovers, develops, and commercializes innovative cancer treatments spanning hematology and solid tumors; its foundational products include the BTK inhibitor BRUKINSA (zanubrutinib) for various blood cancers, the PD-1 inhibitor TEVIMBRA (tislelizumab) approved as a neoadjuvant/adjuvant treatment for non-small cell lung cancer (NSCLC), and pamiparib, alongside a pipeline encompassing sonrotoclax (BCL2 inhibitor), tarlatamab, zanidatamab, blinatumomab, BGB-26808, BGB-R046, BG-68501, and others targeting breast, lung, and gastrointestinal cancers through platforms in multi-specific antibodies, protein degraders, and antibody-drug conjugates. Founded in 2010 by John V. Oyler and Xiaodong Wang and headquartered in Cambridge, Massachusetts, with significant operations in Basel, Switzerland following its 2025 redomiciliation, Shanghai and Suzhou, China, and facilities across more than 40 markets on six continents including the United States, Europe, Australia, and Thailand, the company employs over 11,000 colleagues and maintains in-house research, clinical development, and manufacturing capabilities highlighted by the 2024 opening of its Princeton West Innovation Campus in New Jersey for biologics production. Recent developments include positive topline Phase 3 results for sonrotoclax in relapsed or refractory chronic lymphocytic leukemia (CLL) announced in August 2025, European Commission approval of TEVIMBRA for NSCLC in August 2025 ahead of late-breaking data presentations, an $885 million upfront royalty deal with Royalty Pharma on Amgen's tarlatamab in August 2025 retaining rights to related assets like xaluritamig, third quarter 2025 revenues of $1.4 billion reflecting 41% growth, and positive Phase 3 results for ZIIHERA as a HER2-targeted therapy in November 2025, alongside over 170 clinical trials involving more than 25,000 patients and treatments reaching 1.7 million patients globally.
Company News
BeOne Medicines to Announce Third Quarter 2026 Financial Results on November 5
Oncolytics Biotech (TSE:ONC) Share Price Breaks Above Two Hundred Day Moving Average – Should You Sell?
BeOne Medicines Highlights Rapidly Accelerating Solid Tumor Franchise at ESMO 2026
BeOne Medicines (NASDAQ:ONC) Insider Sells $10,890,166.73 in Stock
All You Need to Know About BeOne Medicines Ltd. - Sponsored ADR (ONC) Rating Upgrade to Strong Buy
New Strong Buy Stocks for October 15th
Comparing Aurora Cannabis (NASDAQ:ACB) & BeOne Medicines (NASDAQ:ONC)
Oncolytics Biotech (TSE:ONC) Share Price Crosses Below 200 Day Moving Average – Here’s Why
Biotech Leader BeOne Medicines Poised To Hit Early Buy Points
BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) Stock Has Consensus Target Price of $402.71
Head-To-Head Analysis: BeOne Medicines (NASDAQ:ONC) versus NRx Pharmaceuticals (NASDAQ:NRXP)
BeOne Medicines AG (ONC) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
BeOne Medicines (NASDAQ:ONC) Insider Sells $13,365,991.70 in Stock
Oncolytics Biotech (TSE:ONC) Shares Pass Above Two Hundred Day Moving Average – Here’s Why
Nykredit A S Invests $1.20 Million in BeOne Medicines Ltd. – Sponsored ADR $ONC
Trump's MFN Push Goes Beyond Big Pharma, Adds 9 Mid-Sized Drugmakers
BeOne Medicines to Present at the Morgan Stanley Annual Global Healthcare Conference
BeOne Medicines Announces Voluntary Agreement with U.S. Government to Expand Access to Innovative Cancer Medicines
BeOne Medicines Announces New Phase 3 Survival Data Reinforcing Benefit of ZIIHERA-Containing Regimens in First-Line HER2+ Gastroesophageal Cancer
BeOne Medicines Ltd. - Sponsored ADR (ONC) is a Great Momentum Stock: Should You Buy?